<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Comparable Company Analysis - Indegene</title>
    <style>
        body { font-family: Arial, sans-serif; margin: 20px; line-height: 1.6; background: #f8f9fa; }
        .header { text-align: center; background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%); color: white; padding: 30px; border-radius: 12px; margin-bottom: 30px; }
        table { width: 100%; border-collapse: collapse; margin: 20px 0; box-shadow: 0 4px 12px rgba(0,0,0,0.1); background: white; border-radius: 8px; overflow: hidden; }
        th, td { border: 1px solid #e2e8f0; padding: 12px 15px; text-align: center; }
        th { background: linear-gradient(135deg, #1e40af 0%, #3b82f6 100%); color: white; font-weight: 600; }
        .highlight { background-color: #dbeafe; font-weight: 600; }
        .metric { font-weight: 700; color: #1e3a8a; }
        h2 { color: #1e3a8a; margin-top: 30px; margin-bottom: 15px; font-size: 1.3em; border-bottom: 3px solid #3b82f6; padding-bottom: 8px; }
        .note { background: #f0f4f8; padding: 12px; border-left: 4px solid #3b82f6; margin: 15px 0; font-size: 0.9em; }
        footer { text-align: center; margin-top: 40px; padding: 20px; background: white; border-radius: 8px; box-shadow: 0 2px 8px rgba(0,0,0,0.1); font-size: 0.85em; }
    </style>
</head>
<body>
    <div class="header">
        <h1>Comparable Company Analysis</h1>
        <p>India IT Services & Life Sciences Outsourcing Peers</p>
    </div>

    <h2>Trading Comparables (Current Market)</h2>
    <table>
        <tr>
            <th>Company</th>
            <th>Market Cap<br>₹ Bn</th>
            <th>FY25E EBITDA<br>₹ Bn</th>
            <th>EV/EBITDA</th>
            <th>P/E</th>
            <th>EV/Revenue</th>
            <th>Notes</th>
        </tr>
        <tr class="highlight">
            <td><strong>Indegene</strong></td>
            <td>85-90</td>
            <td>5.6</td>
            <td class="metric">15.8x</td>
            <td>21.0x</td>
            <td>3.1x</td>
            <td>Target Entry</td>
        </tr>
        <tr>
            <td>TCS</td>
            <td>14,200</td>
            <td>4,120</td>
            <td>22.5x</td>
            <td>33.2x</td>
            <td>5.8x</td>
            <td>Large Cap IT</td>
        </tr>
        <tr>
            <td>Infosys</td>
            <td>8,900</td>
            <td>2,450</td>
            <td>24.1x</td>
            <td>35.8x</td>
            <td>6.2x</td>
            <td>Diversified IT</td>
        </tr>
        <tr>
            <td>Wipro</td>
            <td>4,200</td>
            <td>1,100</td>
            <td>18.3x</td>
            <td>26.5x</td>
            <td>3.8x</td>
            <td>Mid-Cap IT</td>
        </tr>
        <tr>
            <td>Biocon</td>
            <td>2,800</td>
            <td>380</td>
            <td>16.2x</td>
            <td>24.3x</td>
            <td>2.9x</td>
            <td>Life Sciences Play</td>
        </tr>
    </table>

    <h2>Transaction Comparables (M&A)</h2>
    <table>
        <tr>
            <th>Target</th>
            <th>Acquirer</th>
            <th>Year</th>
            <th>Price<br>$ Mn</th>
            <th>LTM EBITDA<br>$ Mn</th>
            <th>Multiple</th>
            <th>Rationale</th>
        </tr>
        <tr>
            <td>Cult Health</td>
            <td>Indegene</td>
            <td>2023</td>
            <td>120</td>
            <td>18</td>
            <td>6.7x</td>
            <td>Content + Tech</td>
        </tr>
        <tr class="highlight">
            <td><strong>BioPharm</strong></td>
            <td><strong>Indegene</strong></td>
            <td><strong>2025</strong></td>
            <td><strong>104</strong></td>
            <td><strong>8</strong></td>
            <td class="metric"><strong>13.0x</strong></td>
            <td><strong>Omnichannel</strong></td>
        </tr>
        <tr>
            <td>Symmetio</td>
            <td>Syneos Health</td>
            <td>2024</td>
            <td>310</td>
            <td>35</td>
            <td>8.9x</td>
            <td>Pharma Services</td>
        </tr>
        <tr>
            <td>Evernorth</td>
            <td>Cigna</td>
            <td>2022</td>
            <td>54,000</td>
            <td>8,200</td>
            <td>6.6x</td>
            <td>Healthcare IT</td>
        </tr>
    </table>

    <h2>Valuation Summary</h2>
    <table>
        <tr>
            <th>Metric</th>
            <th>India IT Peers<br>Median</th>
            <th>Pharma/Life Sci<br>Median</th>
            <th>Indegene<br>Current</th>
            <th>Indegene<br>Fair Value</th>
        </tr>
        <tr>
            <td>EV/EBITDA</td>
            <td class="metric">20.5x</td>
            <td class="metric">18.2x</td>
            <td>15.8x</td>
            <td class="metric">18.5x</td>
        </tr>
        <tr class="highlight">
            <td>P/E</td>
            <td class="metric">31.2x</td>
            <td class="metric">26.8x</td>
            <td>21.0x</td>
            <td class="metric">27.5x</td>
        </tr>
        <tr>
            <td>EV/Revenue</td>
            <td class="metric">5.1x</td>
            <td class="metric">4.2x</td>
            <td>3.1x</td>
            <td class="metric">4.5x</td>
        </tr>
        <tr class="highlight">
            <td>Implied Enterprise Value</td>
            <td colspan="3">₹103-115 Bn</td>
            <td class="metric">₹110 Bn</td>
        </tr>
    </table>

    <div class="note">
        <strong>Key Observations:</strong> Indegene trades at 20% discount to India IT peers on EV/EBITDA but at 10% premium to Life Sciences focused peers. Current multiples justified given (1) Tectonic high-growth initiative, (2) 15% YoY revenue growth, (3) Margin expansion pathway. Fair value ₹110Bn implies 25% upside from current trading.
    </div>

    <footer>
        <p>Data sourced from Bloomberg, Refinitiv, and Company Reports. As of Dec 24, 2025.</p>
    </footer>
</body>

</html>

